Fulcrum Therapeutics Income Statement (2018-2026) | FULC

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
76.30M
Revenue & cost
Revenue (Quarter)
4.93M5.06M2.59M1.88M1.18M0.69M0.29M0.88M0.76M0.87M80.00M
Operating items
Research & Development (Quarter)
17.08M18.91M17.83M25.02M15.37M18.57M16.71M17.85M18.24M19.00M19.77M17.26M14.64M11.71M13.40M12.99M14.30M15.42M14.08M12.44M
Selling, General & Administrative (Quarter)
8.63M9.71M10.76M11.10M9.71M10.13M11.52M10.32M9.96M9.86M10.06M10.25M8.42M7.72M7.00M6.83M7.56M7.28M8.10M7.46M
Restructuring Costs (Quarter)
0.47M-0.04M2.06M4.32M
Operating Expenses (Quarter)
29.31M
Other Operating Expenses (Quarter)
5.09M
Operating Income (Quarter)
-29.31M
EBIT (Quarter)
-29.31M
Non-operating items
Interest & Investment Income (Quarter)
-0.05M
Other Non Operating Income (Quarter)
Non Operating Income (Quarter)
3.13M
Net income details
EBT (Quarter)
-34.98M
Profit After Tax (Quarter)
-26.23M
Income from Continuing Operations (Quarter)
-34.98M
Consolidated Net Income (Quarter)
-34.98M
Income towards Parent Company (Quarter)
-34.98M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-34.98M
Additional items
EPS (Basic) (Quarter)
-0.46
EPS (Diluted) (Quarter)
-0.46
Shares Outstanding (Quarter)
76.26M
Shares Outstanding (Diluted) (Quarter)
76.26M
EBITDA (Quarter)
-29.31M
Interest Expenses (Quarter)
5.62M